Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Post by Micr1on Oct 26, 2010 1:04pm
418 Views
Post# 17613372

Treatment protocol

Treatment protocolHi all,

I'm pretty glad about what I am hearing about the meeting.  Thanks espescially to Kayday, always love to read your posts.  I have a slight glitch in this sunny portrait though... it seems to me, OT would or should have been part of the treatment protocol, no?  I am far from being a pharma test guru but it surprises me that this, seemingly critical element was not followed upon more seriously... don't want to sound negative, I am still in btw, but just woundering how could that be?


Micr1
Bullboard Posts